Chemical inhibitors of Gm12027, an uncharacterized protein, are chosen based on their known actions on common cellular pathways that could be relevant to this protein's function. These inhibitors target key regulatory molecules and pathways in the cell, potentially impacting the function or regulation of a wide range of proteins, including Gm12027. Staurosporine, Rapamycin, LY294002, Wortmannin, U0126, PD98059, SB203580, SP600125, LY3214996, AZD6244, BMS-354825, and Trametinib are chosen for their broad actions on protein kinases, mTOR, PI3K, MEK, and MAPK pathways. These pathways are central to many cellular processes, including cell growth, proliferation, and signal transduction. Inhibition of these pathways can affect the phosphorylation status, stability, or regulatory mechanisms of a variety of proteins. For Gm12027, inhibition of these pathways could lead to a functional impact on the protein, either by directly affecting its activity or by altering the cellular environment and signaling contexts in which it operates.
While the specific role and pathway involvement of Gm12027 are not characterized, targeting these broad and fundamental cellular processes provides a logical approach to identifying potential inhibitors. The inhibitors selected are based on the premise that Gm12027, like many proteins, is likely to be involved in or regulated by these key cellular pathways. The inhibition of these pathways could therefore offer a means to functionally inhibit Gm12027 in a cellular context.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor. It inhibits a wide range of kinases, potentially affecting the phosphorylation status of Gm12027, which may be critical for its function or stability. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cell growth and proliferation. This inhibition could impact the cellular environment or signaling pathways relevant to Gm12027's function or expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can disrupt signaling pathways potentially involved in the regulation or activity of Gm12027. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, another PI3K inhibitor, could similarly disrupt PI3K-dependent pathways, affecting processes or signaling routes that Gm12027 may be involved in. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, affecting the MAPK/ERK pathway. This pathway is involved in various cellular processes, potentially including those regulated by or involving Gm12027. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, potentially disrupting the MAPK/ERK pathway and thereby affecting processes in which Gm12027 might be involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAP kinase, potentially impacting signaling pathways and cellular processes relevant to Gm12027's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which could affect signaling pathways and cellular processes where Gm12027 might play a role. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $260.00 | ||
LY3214996, an ERK1/2 inhibitor, could affect the ERK pathway, potentially impacting the function or regulation of Gm12027. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib, also a MEK inhibitor, could disrupt the MAPK/ERK pathway, possibly affecting Gm12027's role in cellular processes. | ||||||